Skip to main content
ALL a b c d e f g h i j k l m n o p q r s t u v w x y z #

From Reactive Reporting to Proactive Pharma Intelligence: A Practical Blueprint

From Reactive Reporting to Proactive Pharma Intelligence: A Practical Blueprint
Wednesday, 22 April 2026

Whether it's a gross-to-net trend for the access team or a territory performance review for commercial ops, the process is the same: someone needs an answer, files a request, waits in a data engineering queue, and the business moves on without the insight.

In this session, you'll walk away with a practical blueprint for breaking that cycle — using agentic AI to move from ad-hoc data requests to always-on commercial and market access intelligence. We'll show you how pharma teams are:

  • Collapsing the data-to-insight bottleneck — going from raw data (claims, contracts, prescriber activity, sales performance) to a validated, governed analytics model in a single conversation instead of a multi-week data engineering queue
  • Putting role-specific analytic apps in the hands of the people who act on data — purpose-built for the account director tracking formulary position, the brand lead monitoring launch trajectory, or the field ops manager identifying coverage gaps — with embedded root cause analysis, variance decomposition, and forecasting they can open every morning without touching a BI tool
  • Automating recurring investigations, not just reports — payer performance reviews, HCP targeting analyses, contract compliance monitoring, and brand deep-dives that run on schedule and deliver board-ready findings to the right inbox, personalized by role and region

We'll ground every example in the analytical methods underneath — variance decomposition, root cause analysis, anomaly detection, and forecasting — so you can evaluate the rigor, not just the interface.

This isn't a product demo. It's a working framework you can map against your own data, your own team structure, and your own reporting cadence. Whether you lead market access strategy, commercial analytics, or the ops team that supports both, you'll leave with a clear picture of what's now possible — and what it takes to get there.

Speakers:

Chris Walker, Head of Product Marketing, Tellius
Chris Walker leads Product Marketing at Tellius, where he shapes positioning and go-to-market strategy for the company's AI analytics platform across life sciences. He works closely with pharma commercial and market access teams to translate their success stories onto stages like Gartner, Reuters Events, and PMSA. Previously a Senior Product Marketer at Dataiku and a GTM lead at Gartner, Chris holds an MBA from Carnegie Mellon University.

Nick Pinero, VP, Technical Solutions, Tellius
Nick Pinero is VP, Technical Solutions at Tellius, where he helps pharma commercial teams translate complex data into faster, AI-driven decisions. He works directly with leading pharmaceutical companies — including Novartis, Novo Nordisk, Regeneron, Biogen, Genentech, and AbbVie — guiding them through deployment and helping field force, brand, and commercial analytics teams get more value from their data. Prior to Tellius, Nick was a Lead Data Scientist at IBM, where he built AI and machine learning solutions across healthcare, life sciences, and financial services.

From Insights to Impact: The Evolving Rare Disease Landscape in 2025 and Beyond

From Insights to Impact: The Evolving Rare Disease Landscape in 2025 and Beyond
Wednesday, 26 February 2025

In honor of Rare Disease Month, experts from Sanofi, Novartis and Definitive Healthcare will explore how the rare disease space has evolved and where it is heading in 2025.

This roundtable will provide key insights into how breaking down data silos, fostering collaboration, and focusing on rare diseases within the broader pharma ecosystem can accelerate the development of life-changing therapies.

Key discussion points will include:

  • How Data Access Leads to Better Outcomes: Discussing how seamless access to integrated data—from clinical trials and real-world data- can enhance drug development, support better trial designs, and help pharma companies more efficiently address unmet medical needs in rare diseases.
  • How to Improve Collaboration: Highlighting the critical need for collaboration between pharma companies, healthcare providers, academic institutions, and patient advocacy groups to drive more effective research and development and improve patient access to new therapies.
  • The Future of Rare Disease in Pharma: Reflecting on how the increased focus on rare disease research, combined with better data access, will shape the future of drug development, personalized medicine, and patient care. Panelists will explore how the rare disease space has evolved and where it is heading in the coming years.

Speakers:

Alex Paragios, Regional Business Director (Sanofi)
Alex Paragios has been with Sanofi for 11+ years. In his role, he serves as the Regional Business Director – Northeast Pompe.

Brian Garino, Director, Advanced Analytics (Novartis)
Brian Garino is the Director, Advanced Analytics at Novartis. In his role, he leads predictive analytics practice designed to drive commercial acceleration via personal and digital touch optimization.

Evan Raggi, Principal
Evan Raggi brings 15+ years of data and analytics experience across cpg and healthcare companies. From start ups to fortune 100 companies, Evan has worked for some of the brightest and most innovative companies. At Definitive, Evan partners with our largest biopharma clients to help problem solve leveraging our entire portfolio of products and services.

From POC to Production. Navigating GenAI Implementation in Life Sciences

From POC to Production. Navigating GenAI Implementation in Life Sciences
Wednesday, 07 August 2024

Generative AI (GenAI) is revolutionizing the life sciences industry, with innovative proofs of concept (POCs) and use cases emerging rapidly. The opportunity now lies in determining how to advance these innovations to production, achieve scale, and create meaningful impact.

We’ve analyzed GenAI projects across the pharma and biotech industries and identified six key opportunity areas for teams to address in order to make AI a significant value driver within their organizations.

Join BeiGene and Beghou experts for concrete examples and actionable approaches for: 

  • Kickstarting GenAI implementation and prioritizing use cases to build momentum
  • Building a strong tech foundation with optimal data infrastructure
  • Ensuring high data quality, privacy, and input accuracy 
    Monitoring and improving the model to ensure high performance and responsible AI principles
  • Navigating change management and enabling ownership
  • Moving GenAI forward while stabilizing what’s already been built 

Future of Pharma

Future of Pharma
Wednesday, 12 April 2023

The Pharmaceutical Industry is experiencing significant shifts across the value chain: from the increased focus on SDOH & health equity, to deep tech being embedded across touch-points; with new stakeholders & potential partnerships, emerging channels, the lasting pandemic effect on public distrust, compliance shifts and regulatory challenges; this is a time to Disrupt or Be Disrupted. We will share insights, action and provocations with relevance for Pharma companies exploring growth drivers, resilience through external changes and the application of AI, Data, Automation & Analytics.

Presenters:

  • Sagar Shah, Head, Pharma Practice & Responsible AI, fractal.ai

From Multichannel to Omnichannel: How AI/ML Techniques Help Pharma Organizations Achieve Customer-Centricity, Part 2

From Multichannel to Omnichannel: How AI/ML Techniques Help Pharma Organizations Achieve Customer-Centricity, Part 2
Wednesday, 29 January 2020

Pharma companies are evolving to deliver a true omnichannel experience to their key customers. While it is crucial to develop both a personal and non-personal engagement plan for a multichannel strategy, a vital missing component is to connect next-best interactions and associated messaging across channels to create a harmonized omnichannel experience.

While a rep promotes his/her brand to an HCP, it is not common for the rep to discuss the brand’s digital presence, such as a published whitepaper or upcoming webinar to ensure prescribers are on-board digital channels. On the other end, brand marketers make considerable investments to engage customers using non-personal channels, but have no direct influence or control on the personal channel.

In this webinar series, we will review key challenges of interweaving personal and non-personal promotion to build an omnichannel customer engagement strategy. We will discuss ways to leverage AI/ML techniques to mine insights from complex and messy data and convert these insights to next-best-actions (NBAs) for sales professionals and other marketing channel providers. We will examine digital analytics KEY performance metrics and share an example of how these can be optimized for an email campaign for HCPs or patients. We will also showcase pharma industry-based case studies covering: customer journeys (across multiple digital channels, the journey analytics, and its impact on CX), and the power of AI/ML-based NBA suggestions in enhancing CX.

Part 2 will be focused on operationalizing omnichannel marketing.

Presenters:

  • Devesh Verma and Geeta Padbidri, Axtria (Part 1)
  • Robert Mozenter and Ilker Oruc, Axtria (Part 2)

From Multichannel to Omnichannel: How AI/ML Techniques Help Pharma Organizations Achieve Customer-Centricity, Part 1

From Multichannel to Omnichannel: How AI/ML Techniques Help Pharma Organizations Achieve Customer-Centricity, Part 1
Wednesday, 22 January 2020

Pharma companies are evolving to deliver a true omnichannel experience to their key customers. While it is crucial to develop both a personal and non-personal engagement plan for a multichannel strategy, a vital missing component is to connect next-best interactions and associated messaging across channels to create a harmonized omnichannel experience.

While a rep promotes his/her brand to an HCP, it is not common for the rep to discuss the brand’s digital presence, such as a published whitepaper or upcoming webinar to ensure prescribers are on-board digital channels. On the other end, brand marketers make considerable investments to engage customers using non-personal channels, but have no direct influence or control on the personal channel.

In this webinar series, we will review key challenges of interweaving personal and non-personal promotion to build an omnichannel customer engagement strategy. We will discuss ways to leverage AI/ML techniques to mine insights from complex and messy data and convert these insights to next-best-actions (NBAs) for sales professionals and other marketing channel providers. We will examine digital analytics KEY performance metrics and share an example of how these can be optimized for an email campaign for HCPs or patients. We will also showcase pharma industry-based case studies covering: customer journeys (across multiple digital channels, the journey analytics, and its impact on CX), and the power of AI/ML-based NBA suggestions in enhancing CX.

Part 1 will introduce a omnichannel customer engagement paradigm.

Presenters:

  • Devesh Verma and Geeta Padbidri, Axtria (Part 1)
  • Robert Mozenter and Ilker Oruc, Axtria (Part 2)